ACET 241220 2.50C (ACET241220C2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

ACET241220C2500

Watchlist

0.10
0.000.00%

15min DelayClose Nov 21 16:00 ET

0.10High0.10Low

Intraday

5D
Daily

News

Adicet Bio Reports Q3 2024 Results and Clinical Progress
TipRanksNov 20 22:57 ET
Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET
RTTNewsNov 19 06:34 ET
Adicet Bio Advances Cancer and Autoimmune Trials
TipRanksNov 18 16:34 ET
Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical...
BenzingaNov 18 16:01 ET
Express News | Adicet Opens Enrollment for Adi-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
ReutersNov 18 16:00 ET
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
BusinesswireNov 18 16:00 ET

Comments

Trytosaveabit

Nov 19 05:40

Watching to see if any surprises come from this?

$Adicet Bio (ACET.US)$ Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET

Jaguar8

Nov 18 15:04

NEWS

$Adicet Bio (ACET.US)$
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Adicet Bio, Inc. has launched a Phase 1 clinical trial for ADI-270, targeting metastatic clear cell renal cell carcinoma, marking a significant step in utilizing gamma delta CAR T cell therapies for solid tumors.
The company also began dosing a lupus nephritis patient in a trial for ADI-001, highlighting its focus on autoimmune diseases.
Preliminary data f...

Jaguar8

Nov 16 16:44

My watchlist Monday. Why? +Data from CAR-T cell therapy

$Adicet Bio (ACET.US)$

Jaguar8

Nov 16 15:44

NEWS

$Adicet Bio (ACET.US)$
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
Adicet Bio (NASDAQ: ACET) presented clinical biomarker data for ADI-001, their off-the-shelf gamma delta CAR T cell therapy, at ACR Convergence 2024.
The data showed robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue, with CAR T cell activation levels of 27-64% at the 1E9 do...

Stock_Drift

Nov 16 09:31

$Adicet Bio (ACET.US)$